Cost-Utility Analysis of Treatment Algorithms for Vesicoureteral Reflux
Vesicoureteral Reflux (VUR) is a common pediatric urologic condition that affects approximately 1% of children in the United States (Pohl et al. J Urol 177:1659–1666. https://doi.org/10.1016/j.juro.2007.01.059, 2007). There are a variety of management options and surrounding discourse regarding the optimal treatment course. Based on the 2017 American Urological Association guidelines, treatment options include surveillance with or without antibiotic prophylaxis, surgical reimplantation (open, laparoscopic, or robotic), and minimally invasive endoscopic correction with injectable ureteral bulking agents. The best treatment option depends on several factors including age, reflux grade, breakthrough urinary tract infections, and the presence of renal scarring, bowel/bladder dysfunction, or other congenital abnormalities. The economic impact of these treatment options varies widely, so standardized comparisons that evaluate both costs and outcomes is appropriate.
